Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 55.20M | 59.59M | 72.77M | 84.33M | 78.20M |
Gross Profit | 29.74M | 32.69M | 48.95M | 61.80M | 57.51M |
EBITDA | -30.74M | -36.24M | -8.69M | 7.61M | 11.69M |
Net Income | -40.22M | -43.07M | -13.78M | 2.89M | 7.06M |
Balance Sheet | |||||
Total Assets | 64.83M | 66.77M | 72.95M | 88.09M | 86.22M |
Cash, Cash Equivalents and Short-Term Investments | 12.91M | 14.85M | 20.52M | 40.27M | 36.96M |
Total Debt | 30.99M | 35.99M | 10.53M | 11.17M | 12.18M |
Total Liabilities | 61.12M | 64.70M | 35.18M | 39.55M | 42.44M |
Stockholders Equity | 3.71M | 2.07M | 37.77M | 48.53M | 43.78M |
Cash Flow | |||||
Free Cash Flow | -35.54M | -35.59M | -17.17M | 5.95M | 9.73M |
Operating Cash Flow | -32.14M | -30.92M | -14.11M | 8.52M | 12.28M |
Investing Cash Flow | -1.20M | -4.67M | -3.06M | -2.76M | -2.77M |
Financing Cash Flow | 31.43M | 29.91M | -2.64M | -2.03M | -110.00K |
Allergy Therapeutics reported stable financial performance for the year ending June 2025, with revenues slightly declining to £55.0 million from £55.2 million in 2024. The company is strategically positioned for growth, leveraging its registered product portfolio amid changing German regulations and advancing key R&D programs, including the Grass MATA MPL and VLP Peanut trials. Despite the need for additional funding from August, major shareholders remain supportive, ensuring continued progress in both commercial and innovative pipeline areas.
Allergy Therapeutics has issued 250,674,403 warrants to subscribe for new ordinary shares as part of its financial arrangements with SkyGem Acquisition Limited and Southern Fox Investments Limited. This issuance is linked to a £50 million loan facility, under which the company drew £10 million, necessitating the issuance of warrants. Additionally, 674,403 warrants were issued to Hayfin Healthcare Opportunities LuxCo S.a.r.l. due to anti-dilution rights. This move is part of the company’s strategy to manage its financial obligations and could impact its market positioning by potentially increasing its share capital.
Allergy Therapeutics announced key scientific findings at the EAACI 2025 Congress, highlighting advancements in their research portfolio. The company presented promising results from its peanut allergy vaccine candidate and Grass MATA MPL immunotherapy, both showing potential to transform patient care by improving quality of life and inducing beneficial immune responses. These developments underscore the company’s commitment to expanding its VLP platform in food allergies and enhancing treatment options for allergic diseases.
Allergy Therapeutics, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), announced Dr. Janice Layhadi as the winner of the EAACI Early Career Research Award. This award supports young researchers in allergen immunotherapy, providing essential funding to advance their research. Dr. Layhadi’s work focuses on biomarker discovery in allergen immunotherapy, which is expected to enhance understanding and treatment of allergic conditions, ultimately improving patient outcomes.